Khan Khaleque Newaz, Masuzaki Hideaki, Fujishita Akira, Kitajima Michio, Hiraki Koichi, Miura Seiyou, Sekine Ichiro, Ishimaru Tadayuki
Department of Obstetrics and Gynecology, Nagasaki University School of Medicine, Nagasaki Minicipal Hospital, Japan.
Acta Obstet Gynecol Scand. 2006;85(4):458-66. doi: 10.1080/00016340500432556.
The suitable parameter in PF as well as in serum that may predict the activity of endometriosis is not well described. Therefore, we tried to examine the peritoneal fluid (PF) and serum concentrations of hepatocyte growth factor (HGF) in different revised American Society of Reproductive Medicine (r-ASRM) staging and morphologic appearances of endometriosis in an attempt to determine whether HGF can be clinically useful to predict the activity of pelvic endometriosis.
Peritoneal fluid was collected from 137 women with endometriosis and 57 women without endometriosis during laparoscopy and blood sampling was collected from 37 women with endometriosis and 21 women without endometriosis before laparoscopy. The concentration of HGF in PF and serum was measured by enzyme-linked immunosorbent assay. The ability of isolated macrophages and stroma to secrete HGF in response to lipopolysaccharide (LPS) was evaluated.
A significantly increased concentration of HGF in PF was found in women with endometriosis (1451.75 +/- 90.7 pg/mL) than that in non-endometriosis (1120.5 +/- 77.3 pg/mL, p < 0.01) without any remarkable difference in HGF levels between women with stage I-/II endometriosis and stage III-/IV endometriosis. When we distributed serum and PF levels of HGF according to different color appearances of endometriosis, we found a significantly higher serum and PF levels of HGF in women containing dominant red peritoneal lesions in pelvic cavity (740 +/- 109.3 pg/mL for serum; 1685 +/- 183.4 pg/mL for PF) than those having other pigmented lesions (649 +/- 79.5 pg/mL, p < 0.05 for serum; 1224 +/- 67.8 pg/mL, p < 0.05 for PF) or chocolate cysts (485 +/- 43.1 pg/mL, p < 0.05 for serum; 1118 +/- 83.1 pg/mL, p < 0.01 for PF). Exogenous stimulation with LPS significantly increased the production of HGF in the culture media by macrophages and stroma derived from women with endometriosis than that in women without endometriosis.
These results suggest that women with early or advanced endometriosis as measured by r-ASRM scoring system are not associated with an increase in either serum or PF concentrations of HGF. Rather HGF levels in serum and PF were significantly increased in women harboring blood-filled red peritoneal lesions and may be clinically useful to predict the activity of pelvic endometriosis.
目前关于可预测子宫内膜异位症活动的腹膜液(PF)及血清中的合适参数尚无充分描述。因此,我们试图检测不同修订版美国生殖医学学会(r-ASRM)分期及子宫内膜异位症形态学表现患者的腹膜液(PF)和血清中肝细胞生长因子(HGF)的浓度,以确定HGF是否在临床上有助于预测盆腔子宫内膜异位症的活动情况。
在腹腔镜检查期间,收集了137例子宫内膜异位症患者和57例非子宫内膜异位症患者的腹膜液,并在腹腔镜检查前采集了37例子宫内膜异位症患者和21例非子宫内膜异位症患者的血液样本。采用酶联免疫吸附测定法测量PF和血清中HGF的浓度。评估分离的巨噬细胞和基质对脂多糖(LPS)刺激分泌HGF的能力。
子宫内膜异位症患者PF中HGF浓度(1451.75±90.7 pg/mL)显著高于非子宫内膜异位症患者(1120.5±77.3 pg/mL,p<0.01),I/II期和III/IV期子宫内膜异位症患者的HGF水平无显著差异。当我们根据子宫内膜异位症的不同颜色外观分布HGF的血清和PF水平时,发现盆腔内有主要红色腹膜病变的女性血清和PF中HGF水平显著高于有其他色素沉着病变的女性(血清:740±109.3 pg/mL;PF:1685±183.4 pg/mL)(血清:649±79.5 pg/mL,p<0.05;PF:1224±67.8 pg/mL,p<0.05)或巧克力囊肿患者(血清:485±43.1 pg/mL,p<0.05;PF:1118±83.1 pg/mL,p<0.01)。与非子宫内膜异位症女性相比,LPS的外源性刺激显著增加了子宫内膜异位症女性来源的巨噬细胞和基质在培养基中HGF的产生。
这些结果表明,根据r-ASRM评分系统测量的早期或晚期子宫内膜异位症女性,其血清或PF中HGF浓度均未增加。相反,有血性红色腹膜病变的女性血清和PF中HGF水平显著升高,可能在临床上有助于预测盆腔子宫内膜异位症的活动情况。